These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31268316)

  • 1. 7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.
    Nakhi A; McDermott CM; Stoltz KL; John K; Hawkinson JE; Ambrose EA; Khoruts A; Sadowsky MJ; Dosa PI
    J Med Chem; 2019 Jul; 62(14):6824-6830. PubMed ID: 31268316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel cholic acid derivatives as highly potent agonists for G protein-coupled bile acid receptor.
    Qian M; Luo Z; Hou W; Sun J; Lu X; Zhang Q; Wu Y; Xue C; Zhao S; Chen X
    Bioorg Chem; 2022 Mar; 120():105588. PubMed ID: 34979448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation.
    Casaburi I; Avena P; Lanzino M; Sisci D; Giordano F; Maris P; Catalano S; Morelli C; Andò S
    Cell Cycle; 2012 Jul; 11(14):2699-710. PubMed ID: 22751440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of bile acid receptor agonists in pulmonary disease models.
    Comeglio P; Morelli A; Adorini L; Maggi M; Vignozzi L
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1215-1228. PubMed ID: 28949776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
    Pellicciari R; Gioiello A; Macchiarulo A; Thomas C; Rosatelli E; Natalini B; Sardella R; Pruzanski M; Roda A; Pastorini E; Schoonjans K; Auwerx J
    J Med Chem; 2009 Dec; 52(24):7958-61. PubMed ID: 20014870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity.
    Broeders EP; Nascimento EB; Havekes B; Brans B; Roumans KH; Tailleux A; Schaart G; Kouach M; Charton J; Deprez B; Bouvy ND; Mottaghy F; Staels B; van Marken Lichtenbelt WD; Schrauwen P
    Cell Metab; 2015 Sep; 22(3):418-26. PubMed ID: 26235421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
    Sindhu T; Srinivasan P
    Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chenodeoxycholic Acid Has Non-Thermogenic, Mitodynamic Anti-Obesity Effects in an In Vitro CRISPR/Cas9 Model of Bile Acid Receptor TGR5 Knockdown.
    Teodoro JS; Machado IF; Castela AC; Amorim JA; Jarak I; Carvalho RA; Palmeira CM; Rolo AP
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bile acid receptor TGR5 overexpression is associated with decreased intestinal mucosal injury and epithelial cell proliferation in obstructive jaundice.
    Ji CG; Xie XL; Yin J; Qi W; Chen L; Bai Y; Wang N; Zhao DQ; Jiang XY; Jiang HQ
    Transl Res; 2017 Apr; 182():88-102. PubMed ID: 28034761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and biological evaluation of cholic acid derivatives as potent TGR5 positive allosteric modulators.
    Li Y; Sun J; Wang X; Luo Z; Shao X; Li Y; Cao Q; Zhao S; Qian M; Chen X
    Bioorg Med Chem; 2023 Sep; 92():117418. PubMed ID: 37536263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
    Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile acids: emerging role in management of liver diseases.
    Asgharpour A; Kumar D; Sanyal A
    Hepatol Int; 2015 Oct; 9(4):527-33. PubMed ID: 26320013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5).
    Martin RE; Bissantz C; Gavelle O; Kuratli C; Dehmlow H; Richter HG; Obst Sander U; Erickson SD; Kim K; Pietranico-Cole SL; Alvarez-Sánchez R; Ullmer C
    ChemMedChem; 2013 Apr; 8(4):569-76. PubMed ID: 23225346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells.
    Yanguas-Casás N; Barreda-Manso MA; Nieto-Sampedro M; Romero-Ramírez L
    J Cell Physiol; 2017 Aug; 232(8):2231-2245. PubMed ID: 27987324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.
    Duan H; Ning M; Zou Q; Ye Y; Feng Y; Zhang L; Leng Y; Shen J
    J Med Chem; 2015 Apr; 58(8):3315-28. PubMed ID: 25710631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
    Pellicciari R; Sato H; Gioiello A; Costantino G; Macchiarulo A; Sadeghpour BM; Giorgi G; Schoonjans K; Auwerx J
    J Med Chem; 2007 Sep; 50(18):4265-8. PubMed ID: 17685603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
    Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
    Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased glucagon responsiveness by bile acids: a role for protein kinase Calpha and glucagon receptor phosphorylation.
    Ikegami T; Krilov L; Meng J; Patel B; Chapin-Kennedy K; Bouscarel B
    Endocrinology; 2006 Nov; 147(11):5294-302. PubMed ID: 16916948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
    Katona BW; Cummins CL; Ferguson AD; Li T; Schmidt DR; Mangelsdorf DJ; Covey DF
    J Med Chem; 2007 Nov; 50(24):6048-58. PubMed ID: 17963371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.